Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|August 6, 2020
Catalent to Expand its Argentinian Site
Author(s)Pharmaceutical Technology Editors
The expanded facility will feature two new 40-L and 300-L manufacturing vessels, a capsule filling line, and six drying tunnels that will add more than 10 million doses per annum to the site.
Advertisement
Catalent announced on August 4, 2020 that it is expanding its Argentinian site in Loma Hermosa, Buenos Aires, Argentina, to accommodate more than 11,000 ft2 of production space to handle cytotoxic and highly active products for prescription softgel manufacturing.
The expanded facility will feature two new 40-L and 300-L manufacturing vessels, a capsule filling line, and six drying tunnels that will add more than 10 million doses per annum to the site, a company press release said. The facility is expected to be completed in December 2021.
“This investment will allow the site to grow and handle a wider range of projects, reacting to the increased demands of the industry for high potency treatments in areas such as oncology,” commented Sergio Alter, vice president and general manager, Softgel Technologies, Latin America, in the press release. “Not only will this increase the capacity of the site, but the design of the new facility will see it meet the highest standards of environmental and energy efficiency.”
Source:
Advertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
Symptomatic Dermographism: Novartis Lands Remibrutinib Label Expansion
4
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
5